Our technology

LoopLab’s Fc-Engagers :
An Antigen-Specific Modality to
Induce Immune Tolerance

Fc domains have long been integral to therapeutic proteins. LoopLab’s Fc-Engagers (FcEs) are designed to take this concept further by selectively engaging inhibitory Fc receptors to induce precise, antigen-specific immune tolerance. This approach selectively suppresses harmful immune responses against specific antigens while preserving overall immune function, minimizing unwanted immune suppression.

By leveraging this innovative technology, we aim to transform the treatment of autoimmune diseases and other unwanted immune reactions by overcoming key limitations and side effects of existing therapies.

Exploring Fc-Engager Application
by Smart Delivery using our
SelfAmp technology.

LoopLab’s mission is to establish a new therapeutic class by combining cutting-edge protein engineering with advanced custom-designed delivery systems. Fc-Engagers (FcEs) are designed to precisely modulate immune responses by selectively engaging inhibitory Fc receptors, enabling antigen-specific immune tolerance while keeping beneficial immune responses intact.

To enhance therapeutic efficacy, SelfAmps—our self-amplifying biologic technology—offer a potential delivery system for FcEs, enabling targeted and sustained protein expression within the body. This approach could further expand the possibilities of FcE-based therapies.

By integrating innovative protein-based therapeutics with advanced delivery technologies, LoopLab is redefining the treatment landscape for autoimmune and chronic inflammatory diseases.

Disease Focus Areas

Reimagining the treatment of immunological diseases
Dysregulation of the immune system is at the core of many diseases, affecting billions of people worldwide who still lack effective treatment options. Autoimmune diseases alone impact approximately 10% of the global population, while allergies affect 25–30% of individuals, posing a significant and growing health challenge. Additionally, many biologics trigger anti-drug antibodies (ADAs), limiting their long-term efficacy and treatment potential. Furthermore, currently patients undergoing organ transplantation face an increasing need for effective immunosuppressive therapies to improve long-term outcomes and prevent complications. With a massive global market need for innovative therapies, LoopLab is dedicated to developing next-generation immune-modulating solutions that address these critical challenges.

  1. 1. Autoimmune Diseases

    Autoimmune diseases occur when the immune system mistakenly attacks healthy cells. Our foundational work will pave the way for future breakthroughs in the treatment of numerous chronic autoimmune diseases. Our research is driven by a platform technology, and we are specifically tailoring our FcE technology towards each selected disease.

  2. 2. Allergies

    Allergies occur when the immune system mistakenly identifies harmless substances as threats, triggering an excessive response. This overreaction leads to inflammation, histamine release, and symptoms ranging from mild discomfort to severe anaphylaxis. Unlike infections, allergies stem from immune hypersensitivity rather than a true pathogen attack. By reversing this misdirected response, our Fc-Engager platform technology makes next-generation allergen tolerance therapies feasible.

  3. 3. Anti-drug antibodies

    The immune system sometimes recognizes therapeutic proteins, such as monoclonal antibodies, as foreign, triggering the production of anti-drug antibodies (ADAs). These ADAs can neutralize treatments, reduce efficacy, and cause adverse reactions, limiting long-term therapeutic success. Preventing this immune response is crucial for maintaining drug effectiveness. With our Fc-Engager platform technology, we aim to modulate immune tolerance and prevent ADA formation, ensuring sustained treatment benefits for patients